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Background: Accurate estimates of SARS-CoV-2 infection in different population
groups are important for the health authorities. In Norway, public infection control
measures have successfully curbed the pandemic. However, military training and ser-
vice are incompatible with these measures; therefore extended infection control
measures were implemented in the Norwegian Armed Forces. We aimed to describe
these measures, discuss their value, and investigate the polymerase chain reaction
(PCR) prevalence and seroprevalence of SARS-CoV-2, as well as changes in antibody
titer levels over the 6-week military training period in a young, asymptomatic popula-
tion of conscripts.
Methods: In April 2020, 1170 healthy conscripts (median age 20 years) enrolled in
military training. Extended infection control measures included a pre-enrollment tele-
phone interview, self-imposed quarantine, questionnaires, and serial SARS-CoV-2
testing. At enrollment, questionnaires were used to collect information on symptoms,
and SARS-CoV-2 rapid antibody testing was conducted. Serial SARS-CoV-2 PCR and
serology testing were used to estimate the prevalence of confirmed SARS-CoV-2 and
monitor titer levels at enrollment, and 3 and 6 weeks thereafter.
Results: At enrollment, only 0.2% of conscripts were SARS-CoV-2 PCR-positive, and
seroprevalence was 0.6%. Serological titer levels increased nearly 5-fold over the
6-week observation period. Eighteen conscripts reported mild respiratory symptoms
during the 2 weeks prior to enrollment (all were PCR-negative; one was serology-pos-
itive), whereas 17 conscripts reported respiratory symptoms and nine had fever at
enrollment (all were PCR- and serology-negative).
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Conclusions: The prevalence of SARS-CoV-2 was less than 1% in our sample of
healthy Norwegian conscripts. Testing of asymptomatic conscripts seems of no value
in times of low COVID-19 prevalence. SARS-CoV-2 antibody titer levels increased
substantially over time in conscripts with mild symptoms.
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1 | INTRODUCTION
Current knowledge suggests that children and young adults infected
with SARS-CoV-2 are more often asymptomatic, or have fewer and
milder symptoms than older patients.1-3 Moreover, children and teens
between 10 and 19 years of age may be more likely to spread the
virus among family members than adults and younger children.4 Poly-
merase chain reaction (PCR) testing is mainly performed on symptom-
atic patients, those in need of hospitalization, patients at risk, and
among health care workers. So far, SARS-CoV-2 testing has not been
performed systematically in asymptomatic groups, thus the preva-
lence and rate of transmission in young asymptomatic individuals are
still largely unknown. Accurate estimates of infection within different
population groups are crucial for health authorities when deciding
how and when to close and reopen societies during the COVID-19
pandemic.
Military service in Norway is mandatory for all men and women;
between 7000 and 8000 of them undergo military conscription every
year.5 In order to ensure redundancy, enrollment of new conscripts is a
continuous process in the Norwegian Armed Forces. In Norway, public
infection control measures have successfully curbed the rates of hospi-
tal admissions and deaths due to COVID-19.6 However, military train-
ing and service are not compatible with these measures, as service
personnel live together in barracks, and combat training involves body
contact. Therefore, in mid-April 2020, the Norwegian Armed Forces
implemented extended infection control measures to ensure the con-
tinuation of military training and the health of military personnel. The
measures included a pre-enrollment telephone interview, self-imposed
quarantine before enrollment, questionnaires, and serial SARS-CoV-2
PCR and serology testing during the initial 6-week training period. We
aimed to describe these measures, discuss their value, and investigate
the PCR prevalence and seroprevalence of SARS-CoV-2, as well as
changes in antibody titer levels over the 6-week military training period
in a young, asymptomatic population of conscripts.
2 | MATERIALS AND METHODS
2.1 | Cohort
The study cohort included 1170 healthy conscripts (median age:
20 years, range 18-25), 798 men (68.2%) and 372 women (31.8%),
who enrolled in military training between 19 and April 27, 2020. As
conscripts are called for military service regardless of residential area,
our cohort included men and women from all over Norway.
2.2 | Extended infection control measures
Two weeks prior to enrollment, conscripts were interviewed by tele-
phone to motivate them for military service and ensure compliance
with public infection control measures related to COVID-19. All con-
scripts were encouraged to undergo self-imposed quarantine until
enrollment.
On enrollment day, conscripts underwent an initial screening:
they were asked about current respiratory symptoms, their body tem-
perature was measured using an ear thermometer, and a sample was
taken for rapid antibody testing (performed on site). Individuals with
symptoms, a temperature ≥38.0C, and/or a positive rapid antibody
test underwent further clinical interviews and examinations, and were
then quarantined pending the results of a PCR test (Figure 1).
All conscripts also completed an online questionnaire, which col-
lected information on possible or confirmed COVID-19 over the pre-
vious 2 weeks, compliance with public infection control measures,
and possible close contact with SARS-CoV-2-infected individuals.
2.3 | SARS-CoV-2 rapid antibody test, PCR, and
serology analyses
Capillary blood samples were used for rapid antibody testing (Acro
2019-nCoV IgG/IgM, Acro Biotech Inc., Rancho Cucamonga, Califor-
nia). This test is a lateral flow chromatographic immunoassay for quali-
tative detection of IgG and IgM antibodies to SARS-CoV-2.
Nasopharyngeal swabs were used to collect samples for SARS-CoV-2
PCR at enrollment, and after 3 and 6 weeks of military training. PCR tests
(Roche cobas SARS-CoV-2 RNA test, Roche Diagnostics, Hoffmann-La
Roche, Basel, Switzerland) were run at the Department of Microbiology at
Oslo University Hospital on the Cobas 6800 platform. The cobas SARS-
CoV-2 RNA test is a single-well dual target assay, which includes both spe-
cific detection of SARS-CoV-2 and pan-Sarbecovirus detection for the Sar-
becovirus subgenus family that includes SARS-CoV-2.7
Venous blood samples were collected using VACUETTE Blood
Collection Tubes (Greiner Bio-One, Kremsmünster, Austria) for
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SARS-CoV-2 serology testing at enrollment, and after 3 and 6 weeks
of military training. Samples were analyzed at the Department of
Microbiology at Oslo University Hospital, using the Elecsys anti-
SARS-CoV-2 IgM/IgG assay fully automated on the Cobas e801 ana-
lyzer (Roche Diagnostics). The assay measures the combined total of
IgM and IgG against the nucleocapsid (N) structural protein of SARS-
CoV-2 and provides results as a cutoff index (COI) calculated based
on signal sample/assay cutoff. A COI above 1.2 was defined as a
positive result.
2.4 | Ethics
Data resulting from the implementation of extended infection con-
trol measures in the Norwegian Armed Forces are administered by
the Norwegian Armed Forces Health Registry (NAFHR), a central
health registry with data from Norwegian Armed Forces personnel,
including conscripts, and civilian and military staff. Current regula-
tions authorize the NAFHR to produce anonymous statistics for
research purposes.8
F IGURE 1 Extended infection control measures in the Norwegian Armed Forces
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3 | RESULTS
On enrollment day, 17 (1.4%) of the 1170 conscripts reported mild
respiratory symptoms, and nine (0.8%) had a body temperature
≥38.0C. None of these conscripts was SARS-CoV-2 PCR-positive, or
serology-positive at enrollment.
Two of the 1170 conscripts were both SARS-CoV-2 rapid anti-
body test IgG- and IgM-positive, 25 were IgM-positive only, and
29 were IgG-positive only. Of the 1170 conscripts, seven were both
SARS-CoV-2 rapid antibody test IgG-positive and serology-positive
(Table 1), while none were rapid antibody test-negative and serology-
positive. Using the serological test at Oslo University Hospital as the
gold standard, the sensitivity of the SARS-CoV-2 rapid antibody test
was calculated to be 100%. Of the 56 conscripts who were SARS-
CoV-2 rapid antibody test-positive, 49 were serology-negative,
whereas 1114 were both serology-negative and rapid antibody test-
negative. Therefore, a total of 1163 were serology-negative, and the
specificity of the SARS-CoV-2 rapid antibody test was calculated to
be 96%. In this cohort, which had a seroprevalence at enrollment of
0.6%, the positive predictive value of the rapid antibody test was cal-
culated to be 13%.
In the online questionnaire, 18 conscripts (1.5%) reported mild
respiratory symptoms during the 2 weeks prior to enrollment.
Reported symptoms included runny nose and sneezing (72%), stuffy
nose (61%), cough (55%), sore throat (33%), headaches (33%), short-
ness of breath (16%), fever (13%), reduced sense of taste or smell
(11%), sore muscles (11%), and dizziness (6%). None of these 18 con-
scripts reported any respiratory symptoms on enrollment day. None
was SARS CoV-2 PCR-positive at enrollment, but one was serology-
positive. Nine conscripts (0.8%) answered “yes” to the question “Do
you think you have had COVID-19?”. Among these, one was SARS-
CoV-2 PCR-positive and four were serology-positive at enrollment.
Two of the 1170 conscripts were SARS-CoV-2 PCR-positive at
enrollment, and one conscript who was initially PCR-negative tested
positive at week 6 (Table 1). None of these individuals reported any
symptoms during the 2 weeks prior to enrollment, at enrollment, or
during the observation period. However, during additional clinical
interviews, the two conscripts who were PCR-positive at enrollment
reported illness with symptom onset 4 and 7 weeks prior to enroll-
ment, respectively. The individual who tested positive at week 6 had
not been ill, and experienced no symptoms before or during the
6-week observation period.
During the 6-week observation period, a total of eight con-
scripts were SARS CoV-2 serology-positive, one female, and seven
males. Seven conscripts (0.6%) were SARS-CoV-2 serology-positive
at enrollment (Table 1), including the three who were also PCR-posi-
tive, and one was SARS-CoV-2 PCR-negative and serology-negative
at enrollment, but developed positive and rising titers at weeks
3 and 6. None of these eight conscripts had fever or reported respi-
ratory symptoms at enrollment, nor did they report any respiratory
symptoms during the observation period. One reported mild respira-
tory symptoms during the 2 weeks prior to enrollment. However,
based on the additional clinical interview, six of the eight SARS-
CoV-2 serology-positive conscripts had been ill with symptom onset
3 to 7 weeks before enrollment (Table 1). Antibody titers increased
almost 5-fold during the 6-week observation period in all but one of
the eight SARS-CoV-2 serology-positive conscripts (Table 1 and
Figure 2).
TABLE 1 SARS-CoV-2 rapid antibody test, PCR, and serology results at enrollment (W0), week 3 (W3), and week 6 (W6), number of days
















1 pos neg neg neg 57.4 66.0 51.7 48 days Dry cough 2 days
2 pos neg neg neg 19.6 24.3 27.0 33 days Headache, fatigue, dry cough,
stuffy nose, nausea
5 days
3 pos neg neg neg 19.2 67.8 92.3 22 days Loss of taste and sense of smell, a
little headache
10 days
4 pos pos neg neg 19.2 62.1 89.1 30 days Sore throat, cough, headache,
heavy breathing during activity,
loss of taste and sense of smell
10 days
5 pos neg neg pos 18.7 20.3 23.2 Not ill No symptoms
6 pos pos neg neg 16.2 40.4 52.0 49 days Stuffy nose, slight cough,
reduced taste
5 days
7 pos neg neg neg 2.1 2.9 7.4 39 days Fever, fatigue, runny nose,
headache, chest pain, muscle
pain
10 days
8 neg neg neg neg 0.6 1.5 1.6 Not ill No symptoms
Abbreviation: COI, cutoff index.
aCOI for positive test = 1.2.
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4 | DISCUSSION
In this study of 1170 healthy conscripts, the seroprevalence of SARS-
CoV-2 was 0.6%, and 0.2% were SARS-CoV-2 PCR-positive on the
day of enrollment to military service. Eighteen conscripts reported
mild respiratory symptoms during the 2 weeks prior to enrollment (all
were PCR-negative, one was serology-positive), whereas 17 conscripts
reported respiratory symptoms and nine had fever at enrollment (all
were PCR- and serology-negative). These low numbers may partly be
due to the high awareness of public infection control measures in
Norway during the observation period, which was 3 to 4 weeks after
the pandemic peaked in the country at the end of March/beginning of
April 2020.
4.1 | SARS-CoV-2 rapid antibody test, PCR,
and serology analyses
The sensitivity and specificity of the rapid antibody test used in this
study were 100% and 96%, respectively. The relatively large proportion
of false-positive rapid antibody tests is probably partly due to the fact
that the manufacturer's instructions recommended that “The intensity
of the color in the test line regions may vary depending on the concentra-
tion of SARS-CoV-2 antibodies present in the specimen. Therefore, any
shade of color in the test line region should be considered positive.”9 This
may have resulted in negative tests being interpreted as positive based
on nearly invisible lines in the test field, and illustrates that adequate
instruction and training of health personnel is crucial when introducing
and using new rapid tests. The Acro rapid antibody test has recently
been evaluated by the Norwegian Organization for Quality Improve-
ment of Laboratory Examinations and was rated “acceptable,” with a
sensitivity of 0.88 and a specificity of 0.99.10
Two conscripts were SARS-CoV-2 PCR-positive at enrollment,
and one tested PCR-positive after 6 weeks. Whether this represented
ongoing or previous subclinical infection is unclear. PCR assays detect
the presence of viral RNA. Whether positive SARS-CoV-2 PCR repre-
sents viable and contagious virus, or only viral remnants, does vary
depending on patients and stages of disease. One study found that
infectivity peaked 3 days after symptom onset, and the authors were
not able to culture the virus from samples obtained more than 8 days
after symptom onset.11
Eight of the 1170 conscripts (0.7%) were seropositive for SARS
CoV-2 IgG during the observation period. As antibodies against SARS-
CoV-2 can be detected in the middle and later stages of the COVID-
19 illness,12 testing may help confirm COVID-19 diagnoses in individ-
uals who have not previously been referred to PCR testing. System-
atic antibody testing may also shed light on the actual prevalence of
COVID-19 in the general population, and thus their immunization sta-
tus, which is key to the overall pandemic response in most countries.
Recent studies have revealed prevalence numbers in the range of 1%
F IGURE 2 Titers of SARS CoV-2 IgG antibodies at enrollment (W0), week 3 (W3), and week 6 (W6) for the eight conscripts with positive
serology during the observation period. ID numbers correspond to Table 1
BORUD ET AL. 5 of 7
to 5% in European countries.13 Our results indicate that the preva-
lence of COVID-19 among young, asymptomatic adults in Norway is
less than 1%, which is in agreement with recent mathematical esti-
mates from the Norwegian Institute of Public Health.6
Six of eight seropositive conscripts, among whom two were also
SARS-CoV-2 PCR-positive, had a history of symptoms compatible
with COVID-19, with symptom onset between 3 and 7 weeks before
enrollment. Their titer levels increased nearly 5-fold over the 6-week
observation period, but they reported no new symptoms. Most people
infected with SARS-CoV-2 display an antibody response between
10 and 14 days after infection; however, the antibody response may
depend on disease severity.14 In some mild cases, antibody detection
is only possible long after symptom onset, and in a few cases, anti-
bodies are not detected at all, at least not during the time scale of the
reported studies.15 The duration of antibody response is still
unknown, but it is known that antibodies to other coronaviruses wane
over time (range: 12-52 weeks from the onset of symptoms).15 One
study found that SARS-CoV-2 IgM and IgG antibody levels may
remain for 7 weeks after symptom onset.16
The symptoms and disease reported by the aforementioned six
seropositive conscripts were mild. COVID-19 is generally considered a
mild disease in adolescents.2,3,17 One of the questions that requires fur-
ther study is to what extent young COVID-19 patients actually present
with no symptoms at all, which may increase the risk of spreading the
virus to others. Our study confirms that symptoms are generally mild
among young adults, but hardly supports the idea of frequent occur-
rence of asymptomatic spreaders; at least not in Norway.1
4.2 | Value of testing and self-reported data
Testing of asymptomatic conscripts in our study cohort did not iden-
tify any individuals suspected of active transmission, as both con-
scripts who were PCR-positive at enrollment had been symptom-free
for more than 20 days when they were tested. Seven of the eight
conscripts with a positive serology result during the observation
period had been symptom-free for at least 14 days before enrollment.
Testing of symptomatic conscripts, on the other hand, is widely
recommended,18 and is used as both as a diagnostic tool and a screening
method to detect cases of COVID-19 in areas with active outbreaks.
The incidence numbers in Norway have remained under 5% throughout
the pandemic. Symptomatic testing in this study cohort did not confirm
SARS-CoV-2 infection in any of the 26 conscripts who reported having
mild respiratory symptoms or who had fever at enrollment.
Only one of the eight people with positive serology result during
the observation period reported respiratory symptoms during the
14 days before enrollment. Given the reported time of symptom
onset among all eight conscripts, five would probably have been con-
tagious if they had been enrolled a month earlier, and three might
have presented symptoms of COVID-19. Therefore, self-reported
data and questionnaires could be effective tools in the detection of
COVID-19, especially in combination with symptom-based testing.
Asymptomatic testing does not seem justified, given the low
prevalence and corresponding low predictive value of tests in this
cohort of young healthy conscripts.
5 | CONCLUSION
The prevalence of SARS-CoV-2 was less than 1% in our sample of
healthy Norwegian conscripts. Self-reported symptoms and question-
naires may prove useful in detecting COVID-19, especially in combi-
nation with symptom-based testing. Asymptomatic testing seems of
no value in times of low COVID-19 prevalence. SARS-CoV-2 antibody
titer levels increased substantially over time in young adults with rela-
tively mild symptoms.
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